^
Association details:
| Biomarker: | RB1 deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) + SRA515 (BET inhibitor, BRD4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AZD5153 reverses palbociclib resistance in ovarian cancer by inhibiting cell cycle-related proteins and the MAPK/PI3K-AKT pathway
Published date:
12/20/2021
Excerpt:
Moreover, this study revealed that AZD5153 and palbociclib had a synergistic lethal effect on inducing the cell cycle arrest and increasing apoptosis, even in RB-deficient cell lines. Based on these results, it is anticipated that this class of drugs, including AZD5153, which inhibit the cell cycle-related protein and MAPK/PI3K-AKT pathway, will exhibit synergistic effects with palbociclib in OC.
DOI:
10.1016/j.canlet.2021.12.021
